Brigatinib and Alectinib for ALK Rearrangement-Positive Advanced Non-Small Cell Lung Cancer with or without Central Nervous System Metastasis: A Systematic Review and Network Meta-Analysis
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Brigatinib and Alectinib for ALK Rearrangement-Positive Advanced Non-Small Cell Lung Cancer with or without Central Nervous System Metastasis: A Systematic Review and Network Meta-Analysis
Authors
Keywords
-
Journal
Cancers
Volume 12, Issue 4, Pages 942
Publisher
MDPI AG
Online
2020-04-13
DOI
10.3390/cancers12040942
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis
- (2020) Jesse Elliott et al. PLoS One
- Targeting ALK in Cancer: Therapeutic Potential of Proapoptotic Peptides
- (2019) Arthur Aubry et al. Cancers
- Systematic review with network meta-analysis: indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease
- (2019) Hiroto Miwa et al. JOURNAL OF GASTROENTEROLOGY
- Indirect Comparison of Ropinirole and Pramipexole as Levodopa Adjunctive Therapy in Advanced Parkinson’s Disease: A Systematic Review and Network Meta-Analysis
- (2019) Hongxin Zhao et al. ADVANCES IN THERAPY
- Lung Cancer
- (2019) Faria Nasim et al. MEDICAL CLINICS OF NORTH AMERICA
- Anaplastic lymphoma kinase inhibitors in non-small cell lung cancer patients with brain metastases: a meta-analysis
- (2019) Zhiguo Zhang et al. Journal of Thoracic Disease
- The Transcriptional Roles of ALK Fusion Proteins in Tumorigenesis
- (2019) Stephen P. Ducray et al. Cancers
- Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
- (2019) Narjust Duma et al. MAYO CLINIC PROCEEDINGS
- 1586TiPPhase III ALTA-3 study of brigatinib (BRG) vs alectinib (ALC) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)−positive non–small cell lung cancer (NSCLC) that progressed on crizotinib (CRZ)
- (2019) S Popat et al. ANNALS OF ONCOLOGY
- Reslizumab and mepolizumab for moderate-to-severe poorly controlled asthma: an indirect comparison meta-analysis
- (2019) Kevin Yan et al. Immunotherapy
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Staging Lung Cancer
- (2018) Girish S. Shroff et al. RADIOLOGIC CLINICS OF NORTH AMERICA
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer
- (2018) D. Ross Camidge et al. NEW ENGLAND JOURNAL OF MEDICINE
- The efficacy and safety of ALK inhibitors in the treatment of ALK-positive non-small cell lung cancer: A network meta-analysis
- (2018) Junsheng Fan et al. Cancer Medicine
- Receptor Tyrosine Kinase-Targeted Cancer Therapy
- (2018) Toshimitsu Yamaoka et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial
- (2017) Dong-Wan Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
- (2017) Toyoaki Hida et al. LANCET
- Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
- (2017) Solange Peters et al. NEW ENGLAND JOURNAL OF MEDICINE
- The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancers
- (2017) Joshua K Sabari et al. OncoTargets and Therapy
- The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models
- (2016) Sen Zhang et al. CLINICAL CANCER RESEARCH
- Extended Survival and Prognostic Factors for Patients WithALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastasis
- (2016) Kimberly L. Johung et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase
- (2016) Wei-Sheng Huang et al. JOURNAL OF MEDICINAL CHEMISTRY
- The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
- (2015) Brian Hutton et al. ANNALS OF INTERNAL MEDICINE
- Alectinib Salvages CNS Relapses in ALK-Positive Lung Cancer Patients Previously Treated with Crizotinib and Ceritinib
- (2015) Justin F. Gainor et al. Journal of Thoracic Oncology
- Targeting brain metastases in ALK-rearranged non-small-cell lung cancer
- (2015) Isabella Zhang et al. LANCET ONCOLOGY
- Prospective screening for ALK: Clinical features and outcome according to ALK status
- (2014) Vincent Fallet et al. EUROPEAN JOURNAL OF CANCER
- Evidence Synthesis for Decision Making 3
- (2013) Sofia Dias et al. MEDICAL DECISION MAKING
- Evidence Synthesis for Decision Making 4
- (2013) Sofia Dias et al. MEDICAL DECISION MAKING
- Comparison of clinical characteristics between patients with ALK-positive and EGFR-positive lung adenocarcinoma
- (2013) Hyo Jae Kang et al. RESPIRATORY MEDICINE
- Evidence Synthesis for Decision Making 2
- (2012) Sofia Dias et al. MEDICAL DECISION MAKING
- The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: an indirect comparison in a systematic review
- (2012) J. A. Ford et al. BMJ-British Medical Journal
- CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant
- (2011) Hiroshi Sakamoto et al. CANCER CELL
- Conducting Indirect-Treatment-Comparison and Network-Meta-Analysis Studies: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 2
- (2011) David C. Hoaglin et al. VALUE IN HEALTH
- Interpreting Indirect Treatment Comparisons and Network Meta-Analysis for Health-Care Decision Making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1
- (2011) Jeroen P. Jansen et al. VALUE IN HEALTH
- Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial
- (2010) Georgia Salanti et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
- (2009) Alessandro Liberati et al. PLOS MEDICINE
- Bayesian Meta-Analysis of Multiple Treatment Comparisons: An Introduction to Mixed Treatment Comparisons
- (2008) Jeroen P. Jansen et al. VALUE IN HEALTH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search